Sector News

Feds almost ready to charge drugmakers—and executives—in generics price-fixing probe

April 26, 2018
Life sciences

U.S. prosecutors have been digging into potential price-fixing in the generics world, and along the way, they’ve searched corporate offices and tracked executive movements at industry conferences. Now they’re close to slapping charges on two companies and several execs, Bloomberg reports.

The charges could come this summer, according to Bloomberg’s sources, but those sources didn’t disclose which companies—or executives—would be targeted.

One revelation from the reporting? The feds raided Mylan’s headquarters in September 2016 when CEO Heather Bresch was testifying to Congress about EpiPen price hikes, a source told Bloomberg.

Mylan didn’t immediately respond to a request for comment. The federal generic price-fixing investigation is separate from Mylan’s EpiPen pricing controversy, which started in 2016 and continued into 2017.

Authorities have also searched Perrigo’s offices, the company disclosed last year.

Federal authorities have been investigating possible price fixing in the generics industry for years, leading to regular disclosures by companies that they are under investigation. The government arrested former Heritage Pharma executives in late 2016 and secured a plea deal in 2017 in exchange for their cooperation with the probe.

Since then, state attorneys general—led by Connecticut AG George Jepsen—have filed a civil lawsuit against 18 companies and two executives alleging price fixing on 15 drugs. Mylan president Rajiv Malik was named as a defendant, and the company at the time said it stands by its executive.

“Mylan and Rajiv Malik both intend to defend this case vigorously, and we look forward to the opportunity to present a full defense,” the company said in a statement at the time.

In a document published alongside the lawsuit, Jepsen’s office said the original allegations are the “tip of the iceberg” of alleged pricing collusion.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach